iRhythm Technologies, Inc. (NASDAQ:IRTC) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.51 per share.
For the full year, analysts predict revenues of $ 250.98 million, while looking forward to loss of $ 1.98 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 280.00 million ~ $ 290.00 million
Click Here For More Historical Outlooks Of iRhythm Technologies, Inc.
Previous Quarter Performance
iRhythm Technologies, Inc. announced loss for the second quarter of $ 0.75 per share, from the revenue of $ 50.88 million. The quarterly revenues decreased 4.59 percent compared with the same quarter last year. Street analysts expected iRhythm Technologies, Inc. to report loss of $ 0.80 per share on revenue of $ 42.19 million for the second quarter. The bottom line results beat street analysts by $ 0.05 or 6.25 percent, at the same time, top line results outshined analysts by $ 8.69 million or 20.60 percent.
Stock Performance
Shares of iRhythm Technologies, Inc. traded up $ 4.96 or 2.24 percent on Wednesday, reaching $ 225.96 with volume of 290.20 thousand shares. iRhythm Technologies, Inc. has traded high as $ 233.35 and has cracked $ 221.08 on the downward trend
The closing price of $ 225.96, representing a 292.96 % increase from the 52 week low of $ 56.24 and a 15.34 % decrease over the 52 week high of $ 261.05.
The company has a market capital of $ 6.52 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Recent Analyst recommendations
- On 11th September 2020, initiated by Needham & Company LLC at Hold rating.
Conference Call
iRhythm Technologies, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.iRhythmTech.com
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patients heartbeats and ECG data.
